Preimplantation Genetic Testing (PGT) Market - By Product & Services, By Technology, By Application, By End Use, Global Forecast, 2024 - 2032

Preimplantation Genetic Testing (PGT) Market Size

The global preimplantation genetic testing market was valued at USD 780.8 million in 2023 and is estimated to grow at a CAGR of 9.4% from 2024 to 2032. The market growth is primarily driven by increasing prevalence of genetic disorders in newborns and rising awareness of reproductive health. PGT provides a proactive approach to identifying genetic abnormalities in embryos before implantation, addressing the concerns of families seeking to prevent hereditary diseases.
 

Also, growing advancements in reproductive technologies, particularly in vitro fertilization (IVF), have improved the accessibility of PGT. The rising maternal age and declining fertility rates further support the market's growth, as couples increasingly consider genetic testing to ensure healthy pregnancies. For instance, the Society at a Glance 2024 edition reported a concerning decline in fertility rates, particularly in countries such as Italy, Spain, and Korea. These countries are experiencing exceptionally low fertility rates, resulting in increasing pressure on couples to maximize their chances of successful pregnancies.

This trend is expected to boost the demand for PGT services as more couples seek to ensure genetic health, thereby driving market growth. Additionally, societal acceptance of assisted reproductive technology (ART) and genetic testing is poised to project significant expansion in the coming years.

PGT is a reproductive technology used during IVF to screen embryos for genetic abnormalities before implantation. This process involves extracting a few cells from an embryo and analyzing them for specific genetic conditions or chromosomal disorders.
 

Preimplantation Genetic Testing Market Trends

Growing advancements in PGT technologies significantly propel market demand by enhancing the accuracy, efficiency, and accessibility of genetic screening. Innovations such as next generation sequencing (NGS), allow for comprehensive analysis of embryos, enabling the detection of chromosomal abnormalities and specific genetic disorders with greater precision.
 

• For instance, in July 2023, Thermo Fisher Scientific launched two new NGS-based research tools, the Ion ReproSeq PGT-A Kit and the Ion AmpliSeq Polyploidy Kit, designed for PGT for aneuploidy (PGT-A). These tools were intended to enhance genetic screening in IVF and intracytoplasmic sperm injection (ICSI) procedures. This launch strengthens the company's offering and position in the reproductive health research market and supports advancements in genetic testing for healthier pregnancies.
   

Further, advancements in non-invasive PGT techniques transformed ART that aimed to significantly improve the safety and precision of genetic testing in IVF. A breakthrough involves analyzing cell-free DNA (cfDNA) from blastocoel fluid or embryo culture media, eliminating the need for invasive embryo biopsies. These innovations drive the adoption of PGT, further propelling market expansion as more individuals seek advanced reproductive testing.
 

Preimplantation Genetic Testing Market Analysis

Based on product & service, the is segmented into products and services. The product segment dominated the market and is anticipated to grow at 9.3% CAGR over the forecast period.
 

• The product segment dominance was attributed as essential for conducting genetic screening in IVF procedures, as they include the reagents, sequencing kits, and testing consumables required for accurate testing of embryos.
   
• In addition, the rising incidence of genetic disorders and the increasing adoption of IVF fuels the need for these kits and consumables, further fueling the market demand.
   
• Additionally, advancements in NGS and other genetic technologies have led to the development of more efficient, high-precision kits, further increasing their demand.
   
• The recurring nature of consumables also ensures steady revenue generation, making this segment highly profitable.
   

Based on the technology the PGT market is categorized into next generation sequencing (NGS), polymerase chain reaction (PCR), fluorescent in-situ hybridization (FISH), array, and other technologies The NGS segment accounted for the highest market share of 42% in 2023.
 

• NGS technology's prominence was asserted due to its high accuracy, speed, and ability to analyze a broad range of genetic abnormalities.
   
• NGS allows for comprehensive screening of embryos, detecting both chromosomal aneuploidies and specific genetic mutations in a single test. Its ability to sequence multiple embryos simultaneously at a lower cost compared to traditional methods makes it highly efficient.
   
• As fertility clinics and researchers seek more precise results, the adoption of NGS in PGT has grown, driving its market leadership and fueling further advancements in reproductive technology.
   

Based on application, the preimplantation genetic testing market is segmented into aneuploidy screening, structural chromosomal rearrangement, monogenic/single-gene disorder screening, human leukocyte antigen (HLA) typing, and other applications. The aneuploidy screening segment is poised to reach USD 985.7 million by the end of 2032.
 

• Aneuploidy screening dominance was reflected in its widespread adoption among couples seeking to mitigate genetic risks.
   
• Aneuploidy, characterized by an abnormal number of chromosomes, is a leading cause of implantation failures and miscarriages.
   
• By identifying embryos with the correct chromosomal count, PGT-A significantly increases the chances of successful pregnancies and healthy births.
   
• For instance, according to a study conducted by Medpark Hospital, the success rates of PGT-A vary based on age and prior treatment. The study found that women undergoing IVF or ICSI who received PGT-A testing before embryo transfer achieved a remarkable 95% pregnancy success rate across three consecutive frozen embryo transfers. This highlighted the effectiveness of PGT-A in improving outcomes for couples seeking to ensure the health of their embryos, particularly in the context of advanced maternal age or previous reproductive challenges.
   
• Furthermore, the growing awareness of its benefits and advancements in genetic testing technologies further propel this segment's growth, making it a cornerstone of modern reproductive healthcare.
   

Based on end use, the preimplantation genetic testing market is segmented into hospitals & IVF clinics, diagnostic laboratories, fertility centers, and research institutes. The hospitals and IVF clinics segment dominated the market accounting for USD 328.9 million in 2023.
 

• Hospitals and IVF clinics drive significant growth in the market due to high patient volume, enhanced healthcare infrastructure, and the availability of IVF services in both public and private institutions.
   
• Families seeking fertility treatments frequently choose hospitals for their advanced technological capabilities. Additionally, increasing research activities in these facilities are expected to boost testing rates.
   

In 2023, the U.S. accounted for USD 312.2 million in the North American preimplantation genetic testing market and is expected to maintain its dominance throughout the forecast period.
 

• The U.S. prominence is attributed to its widespread adoption of advanced reproductive technologies, such as IVF, and the growing awareness of genetic screening.
   
• According to the U.S. Department of Health and Human Services, infertility affects millions of Americans at some point in their lives. IVF is a crucial fertility treatment, accounting for over 99% of ART procedures. In 2021, approximately 86,146 infants, or 2.3% of all births in the U.S., were conceived through ART, with around 16.6% of these cases involving PGT. The rising prevalence of infertility, combined with increasing awareness of advanced technologies for early diagnosis of disorders, further reinforces the U.S. position in the market.
   
• The U.S. is home to leading fertility clinics and companies offering advanced PGT technologies, further solidifying its dominance in the region's market and driving overall growth.
   

China has experienced the fastest growth in the preimplantation genetic testing market within the Asia-Pacific region.
 

• The growth is attributed to increasing infertility rates and rising awareness of advanced reproductive technologies. The growing number of fertility clinics and enhanced healthcare infrastructure have facilitated greater access to IVF and genetic testing services.
   
• Supportive government policies promoting ART further contribute to this expansion, positioning China as a key player in the Asia Pacific market and driving demand for innovative genetic screening solutions.
   

Germany holds a prominent position in the Europe preimplantation genetic testing market.
 

• Germany's position is driven by its advanced healthcare infrastructure and robust regulatory framework.
   
• The country benefits from increasing public awareness of genetic disorders and the advantages of PGT, encouraging more couples to pursue genetic testing as part of their reproductive planning.
   
• Germany's well-established fertility clinics and access to advanced reproductive technologies further support market growth.
   
• Favorable regulations regarding aneuploidy screening enhance the acceptance and utilization of PGT services, solidifying Germany's role as a leader in this sector within Europe.
   

Saudi Arabia holds a significant share in the Middle East and Africa preimplantation genetic testing market.
 

• Saudi Arabia's position is due to several factors, including increasing awareness of reproductive health and advancements in ART.
   
• The country has invested in modern healthcare infrastructure, with numerous fertility clinics offering PGT services to address rising infertility rates.
   
• Cultural shifts towards family planning and the desire for healthier pregnancies have driven demand for genetic testing. These elements collectively enhance Saudi Arabia's prominence in the region's PGT market, positioning it as a key player in advancing reproductive health solutions.
   

Preimplantation Genetic Testing Market Share

The market is characterized by the presence of several key players leveraging advanced technologies like NGS, array and other technologies comparative genomic hybridization to enhance the accuracy and efficiency of genetic screening. The market also sees emerging players focusing on innovative products and services to capture niche segments. Strategic partnerships, acquisitions, and continuous research and development efforts are common strategies to strengthen market position.
 

Preimplantation Genetic Testing Market Companies

Few of the prominent players operating in the preimplantation genetic testing industry include:

• Agilent Technologies
• Fulgent Genetics
• Genea BIOMEDX
• Illumina
• Medicover Genetics
• Natera
• Revvity 
• RGI
• Takara Bio
• Thermo Fisher Scientific
• Varinos
• Virtus Health
• Vitrolife Group (Igenomix)
   

Preimplantation Genetic Testing Industry News

• In October 2024, Suzhou Basecare Medical secured approval from China's National Medical Products Administration to extend the registration of its innovative PGT-A kit until 2030. This renewal highlighted the kit's demonstrated clinical efficacy, achieving 100% concordance in over 100,000 clinical samples. This approval reinforced Basecare's business expansion in advancing reproductive health technologies.
   
• In April 2024, GenEmbryomics and Progenesis entered a groundbreaking collaboration aimed at improving access to advanced reproductive technologies. This partnership enabled the two companies to provide the benefits of PGT with whole genome sequencing (PGT-WGS) to fertility patients. Progenesis will utilize its state-of-the-art laboratory and facilities, while GenEmbryomics will act as the preferred provider of the Panacea-GenomeScreen PGT-WGS test, the first and only comprehensive PGT-WGS embryo genetic test. This collaboration marked a significant step forward in enhancing genetic screening capabilities for those seeking fertility solutions.
   

The preimplantation genetic testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product & Service

• Products
• Services

Market, By Technology

• Next generation sequencing (NGS)
• Polymerase chain reaction (PCR)
• Fluorescent in-situ hybridization (FISH)
• Array
• Other technologies

Market, Application

• Aneuploidy screening
• Structural chromosomal rearrangement
• Monogenic/single-gene disorder screening
• Human leukocyte antigen (HLA) typing
• Other applications

Market, End Use

• Hospitals & clinics
• Diagnostic laboratories
• Fertility centers
• Research institutes

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • Saudi Arabia
  • South Africa
  • UAE